No Data
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Chengda Pharmaceutical (301201.SZ): The shareholding ratio of Qianhai Shengtai has decreased from 11.48% to 10.91%.
On March 12, Gelonghui reported that Chengda Pharmaceutical (301201.SZ) announced that it had recently received a notice from its shareholder Shenzhen Qianhai Shengtai Investment Enterprise (Limited Partnership) (referred to as "Qianhai Shengtai"), indicating that Qianhai Shengtai had reduced its shareholding by 1% or more. It was noted that from March 6, 2025, to March 11, 2025, Qianhai Shengtai reduced its holdings by a total of 860,000 shares through block trading, accounting for 0.57% of the company's total share capital after deducting shares in the repurchase account. Qianhai Shengtai's shareholding in the company decreased from 17,391,840 shares to 16.
ChengDa Pharmaceuticals' Facility Passes US FDA CGMP Inspection
Chengda Pharmaceutical (301201.SZ) passed the FDA on-site inspection.
Chengda Pharmaceutical (301201.SZ) announced that from November 11 to 15, 2024, it received...
Chengda Pharmaceutical (301201.SZ): Expected loss of 21 million to 29 million yuan for the fiscal year 2024.
Glonghui, January 16 – Chengda Pharmaceutical (301201.SZ) announced its performance forecast for 2024, projecting a net income loss attributable to the shareholders of the listed company of 21 million to 29 million yuan, compared to a profit of 90.98 million yuan in the same period last year; the net income loss after deducting non-recurring gains and losses is estimated to be 50 million to 60 million yuan, compared to a profit of 53.82 million yuan in the same period last year. The revenue for the reporting period is expected to decrease by approximately 16% to 27% year-on-year. Among them: the sales revenue of the Active Pharmaceutical Ingredient business is expected to decline by about 33% year-on-year, mainly due to overstocking of pharmaceutical-grade L-carnitine by customers in 2023, according to the report.
Chengda Pharmaceutical: 2024 Annual Performance Forecast